Paragon and NextDocs Introduce Clinical Optimization Solutions Targeting Life Sciences Firms
Paragon Solutions, a business consulting and information technology services firm, announced the launch of solutions to optimize clinical operations incorporating the NextDocs product suite. The clinical solutions combine the capabilities of the two partners to deploy low-risk, accelerated solutions for life sciences built on Microsoft Office SharePoint Server.
“With the growing adoption of SharePoint within Life Sciences organizations, companies are looking for solution accelerators that leverage enterprise platforms to optimize the end-to-end drug development process,” said Ravi Shankar, vice president of Paragon’s Life Sciences practice. “NextDocs extends SharePoint with capabilities that complement our Clinical Optimization solution strategy,” he said.
The solutions leverage a strategic partnership formed by the companies in September 2009. One of the solutions the companies are introducing as part of the Clinical Optimization Solution portfolio is an integrated investigator portal. The portal is designed to deliver a collaborative environment that enables clinical sponsors and investigators to: negotiate contracts; define and communicating protocols; support site monitoring; manage grants; work with partners; and improve oversight and planning.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
